Jubilant Pharmova slips 11% on USFDA observation, weak Q4 results ...Middle East

Business Standard - Economy
Jubilant Pharmova slips 11% on USFDA observation, weak Q4 results
The United States Food and Drug Administration (US FDA) has classified its inspection of the company's Montreal Canada contract manufacturing (CMO) facility as Official Action Indicated (OAI)

Read More Details
Finally We wish PressBee provided you with enough information of ( Jubilant Pharmova slips 11% on USFDA observation, weak Q4 results )

Apple Storegoogle play

Also on site :